Camurus AB (CAMRF) reports a 52% revenue increase, strategic licensing with Eli Lilly, and EU approval of Oczyesa, despite currency challenges and market hurdles.

"Successful second quarter for Camurus" Summary second quarter 2025 April - June Total revenues grew 52% (65% at CER1) to SEK 676 (445) million Sales of Buvidal® increased 17% (26% at CER1) to SEK ...

Camurus AB (STO:CAMX) presented its second quarter 2025 results on July 17, revealing record financial performance and significant progress across its product portfolio.

Post-operative nausea and vomiting (PONV) market to rise from $2.11B in 2024 to $2.97B in 2029, driven by innovations in ...

Camurus (NASDAQ STO: CAMX) today announced that the European Commission (EC) has granted Oczyesa®, octreotide subcutaneous depot, marketing authorization* for the maintenance treatment in adult ...

Camurus, an international, science-led biopharmaceutical company, announced that the European Commission (EC) has granted Oczyesa, octreotide subcutaneous depot, marketing authorization for the ...

Investing.com -- Almirall (BME: ALM) shares rose on Friday after the company reported a 72.1% increase in net income for the ...